Literature DB >> 12801928

Regulation of Cdc25A half-life in interphase by cyclin-dependent kinase 2 activity.

Alexander P Ducruet1, John S Lazo.   

Abstract

Cdc25A regulates cell cycle progression, has oncogenic and anti-apoptotic activity, and is over-expressed in many human tumors. Phosphorylation by Chk1 and Cds1/Chk2 down-regulates Cdc25A levels in response to genotoxic stresses. Nevertheless, it remains unclear whether Chk1 and Cds1/Chk2 are uniquely responsible for regulating Cdc25A stability during interphase or if other kinase activities contribute. Here we report that treatment of HeLa cells with the cyclin-dependent kinase inhibitor roscovitine caused a concentration- and time-dependent increase in Cdc25A protein levels. Transfection with dominant-negative Cdk mutants demonstrated that only a Cdk2 mutant increased Cdc25A protein levels; Cdk1 and Cdk3 mutants had no effect. The increased Cdc25A protein levels were the result of an increase in the half-life of the protein; no increase in Cdc25A mRNA levels was observed. These results demonstrate Cdk2 kinase activity contributes to the labile nature of Cdc25A during interphase and redefine the nature of the Cdc25A-Cdk2 autoamplification feedback loop.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12801928     DOI: 10.1074/jbc.M303604200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  CyclinD-CDK4/6 complexes phosphorylate CDC25A and regulate its stability.

Authors:  C Dozier; L Mazzolini; C Cénac; C Froment; O Burlet-Schiltz; A Besson; S Manenti
Journal:  Oncogene       Date:  2017-02-13       Impact factor: 9.867

2.  Phosphorylation of CDC25A on SER283 in late S/G2 by CDK/cyclin complexes accelerates mitotic entry.

Authors:  Laurent Mazzolini; Anaïs Broban; Carine Froment; Odile Burlet-Schiltz; Arnaud Besson; Stéphane Manenti; Christine Dozier
Journal:  Cell Cycle       Date:  2016-08-11       Impact factor: 4.534

3.  Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.

Authors:  Tatyana V Masyuk; Brynn N Radtke; Angela J Stroope; Jesús M Banales; Anatoliy I Masyuk; Sergio A Gradilone; Gabriella Bedekovicsne Gajdos; Natasha Chandok; Jason L Bakeberg; Christopher J Ward; Erik L Ritman; Hiroaki Kiyokawa; Nicholas F LaRusso
Journal:  Gastroenterology       Date:  2011-12-07       Impact factor: 22.682

Review 4.  Is Cdc25 a druggable target?

Authors:  John S Lazo; Peter Wipf
Journal:  Anticancer Agents Med Chem       Date:  2008-12       Impact factor: 2.505

5.  SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase.

Authors:  Jianping Jin; Takahiro Shirogane; Lai Xu; Grzegorz Nalepa; Jun Qin; Stephen J Elledge; J Wade Harper
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

6.  The extracellular signal-regulated kinase-mitogen-activated protein kinase pathway phosphorylates and targets Cdc25A for SCF beta-TrCP-dependent degradation for cell cycle arrest.

Authors:  Michitaka Isoda; Yoshinori Kanemori; Nobushige Nakajo; Sanae Uchida; Katsumi Yamashita; Hiroyuki Ueno; Noriyuki Sagata
Journal:  Mol Biol Cell       Date:  2009-02-25       Impact factor: 4.138

7.  Activation of CDC25A phosphatase is limited by CDK2/cyclin A-mediated feedback inhibition.

Authors:  Jennifer P Ditano; Nandini Sakurikar; Alan Eastman
Journal:  Cell Cycle       Date:  2021-06-22       Impact factor: 5.173

8.  Acetylation and deacetylation of Cdc25A constitutes a novel mechanism for modulating Cdc25A functions with implications for cancer.

Authors:  Enerlyn M Lozada; Zdenek Andrysik; Moying Yin; Nicholas Redilla; Kathryn Rice; Peter J Stambrook
Journal:  Oncotarget       Date:  2016-04-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.